Tranzyme, which is developing small molecule therapeutics to treat gastrointestinal disorders, raised $54 million by offering 13.5 million shares at $4. The biotech had originally filed to raise $60 million by offering 5 million shares at a range of $11 to $13....read more
Tranzyme, which is developing small molecule therapeutics to treat gastrointestinal disorders, lowered the proposed deal size for its upcoming IPO on Friday. The Durham, NC-based company now plans to raise $54 million by offering 13.5 million shares at an...read more
Tranzyme, a clinical-stage biotech developing small molecule therapeutics to treat gastrointestinal disorders, announced terms for its IPO on Tuesday. The Durham, NC-based company plans to raise $60 million by offering 5 million shares at a price range of $11...read more
Tranzyme, a clinical-stage biotech developing small molecule therapeutics to treat gastrointestinal disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The Durham, NC-based company, which was founded in 1998 and...read more
Tranzyme prices IPO at $4, well below the original $11-$13 range
Tranzyme, which is developing small molecule therapeutics to treat gastrointestinal disorders, raised $54 million by offering 13.5 million shares at $4. The biotech had originally filed to raise $60 million by offering 5 million shares at a range of $11 to $13....read more
Tranzyme slashes estimated IPO price
Tranzyme, which is developing small molecule therapeutics to treat gastrointestinal disorders, lowered the proposed deal size for its upcoming IPO on Friday. The Durham, NC-based company now plans to raise $54 million by offering 13.5 million shares at an...read more
Biotech Tranzyme sets terms for $60 million IPO
Tranzyme, a clinical-stage biotech developing small molecule therapeutics to treat gastrointestinal disorders, announced terms for its IPO on Tuesday. The Durham, NC-based company plans to raise $60 million by offering 5 million shares at a price range of $11...read more
Tranzyme submits filing for $75 million IPO
Tranzyme, a clinical-stage biotech developing small molecule therapeutics to treat gastrointestinal disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The Durham, NC-based company, which was founded in 1998 and...read more